|
Contents |
|
|
|
Integrative
Medicine
|
|
Treatment
|
|
|
|
|
Integrative
Medicine
|
|
|
|
Fisher
M, Yang LX
Anticancer
effects and mechanisms of polysaccharide-K (PSK): implications of cancer
immunotherapy
Anticancer
Res 2002 May-Jun;22(3):1737-54
|
|
Iino
Y, Takai Y, Sugamata N, Morishita Y
PSK
(krestin) potentiates chemotherapeutic effects of tamoxifen on rat mammary
carcinomas
Anticancer Res 1992 Nov-Dec;12(6B):2101-3
|
|
Kanoh
T, Matsunaga K, Saito K, Fujii T
Suppression
of in vivo tumor-induced angiogenesis by the protein-bound polysaccharide PSK
In Vivo 1994 Mar-Apr;8(2):247-50
|
|
Kudo S, Tanaka J, Kashida H,
Tamegai Y, Endo S, Yamano HO
Effectiveness
of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal
cancer and changes of tumor marker
Oncol Rep 2002 May-Jun;9(3):635-8
|
|
Saito
Y
Long-term
survival of patients with brain tumors treated with ACNU and PSK after
surgery--with special reference to there immunological follow-up
Gan To Kagaku Ryoho 1984 Oct;11(10):2185-92
|
|
Tokuda
K, Abe H, Aida T, Kaneko S, Tsuru M
Effect
of PS-K on experimental neurogenic tumors in rats induced by ethylnitrosourea
Hokkaido Igaku Zasshi 1984 Sep;59(5):639-42
|
|
Zhang
H, Morisaki T, Matsunaga H, Sato N, Uchiyama A, Hashizume K, Nagumo F,
Tadano J, Katano M.
Protein-bound
polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1
and MMPs
Clin Exp Metastasis 2000;18(4):343-52
|
|
|
Treatment
|
|
|
|
Boiardi A, Eoli M, Salmaggi A, Zappacosta
B, Fariselli L, Milanesi I, Broggi G, Silvani A
Efficacy of intratumoral delivery of
mitoxantrone in recurrent malignant glial tumours
J Neurooncol 2001 Aug;54(1):39-47
|
|
Boiardi A, Eoli M, Pozzi A, Salmaggi
A, Broggi G, Silvani A
Locally delivered chemotherapy and repeated
surgery can improve survival in glioblastoma patients
Ital J Neurol
Sci 1999 Feb;20(1):43-8
|
|
Boiardi A, Silvani A, Pozzi A,
Fariselli L, Broggi G, Salmaggi A
Interstitial chemotherapy plus systemic
chemotherapy for glioblastoma patients: improved survival in sequential
studies
J
Neurooncol 1999 Jan;41(2):151-7
|
|
Lashford
LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside
J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D.
Temozolomide
in Malignant Gliomas of Childhood: A United Kingdom Children's Cancer Study
Group and French Society for Pediatric Oncology Intergroup Study
J Clin Oncol 2002 Dec 15;20(24):4684-91
|
|
Grabenbauer
GG, Anders K, Fietkau RJ, Klautke G, Feldmann HJ, Weiser S, Staab HJ, Krauseneck
P, Sauer R
Prolonged
infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in
patients with newly diagnosed glioblastoma--a phase I study
J Neurooncol 2002 Dec;60(3):269-75
|
|
Chaudhry V, Cornblath DR, Corse
A, Freimer M, Simmons-O'Brien E, Vogelsang G
Thalidomide-induced
neuropathy
Neurology 2002 Dec 24;59(12):1872-5
|
|
Green
MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI,
Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ
A randomized
double-blind multicenter phase III study of fixed-dose single-administration
pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive
chemotherapy
Ann Oncol 2003 Jan;14(1):29-35 |
bottom
|
Volume 2, Number 1 - 15
January 2003